Resources>Antibody Industry Trends>Biointron Insights: Antibody Industry Report (Q4 2024 Insights, Trends & Analysis)

Biointron Insights: Antibody Industry Report (Q4 2024 Insights, Trends & Analysis)

Biointron 2025-01-25

Biointron’s Q4 2024 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2024 (October, November, December). This quarter, 6 novel antibody drugs have been approved by at least one regulatory agency around the world: three monoclonal antibodies, two bispecific antibodies, and one antibody-drug conjugate (ADC).

  1. Ongericimab (Junshida)

  2. Marstacimab (Hympavzi)

  3. Zanidatamab (Zilhera)

  4. Sacituzumab tirumotecan (佳泰莱; Sac-TMT)

  5. Zenocutuzumab (Bizengri)

  6. Cosibelimab (Unloxcyt)

Q4 2024 saw several large collaborations and acquisitions of up to USD$1.9 billion in value. Investment in antibody drug startups focused on novel antibody platforms changing glycans, structure, and the use of artificial intelligence.

Gain exclusive insights into current trends such as:

  • 📣 6 novel antibody drugs approved for the first time in Q4

  • 💸 Top 10 antibody drug deals, including collaborations, M&As, and funding rounds of up to US$1.9B

  • 📈 A focus on novel platforms from startups with millions in seed funding

  • 🤖 Exciting uses for AI in antibody discovery

  • 💊 A list of antibody drugs in regulatory review to keep an eye out for in Q1 2025


Please fill in the form below to download


Recommended Articles
Biointron Insights: Antibody Industry Trends (Q3 2026 Insights, Trends & Analysis)

Biointron's Q3 2026 Antibody Industry Trends report aims to explore the events a……

Sep 30, 2026
November 2026: Bispecifics x AI: From Design to Clinic

Bispecific antibodies (BsAbs) can bind two different antigens simultaneously, of……

Nov 09, 2026
Week 1, November 2026: VNAR vs. VHH: What's the Difference Between Shark and Camelid Single-Domain Antibodies?

When we think of antibodies, sharks and alpacas probably aren't the first an……

Nov 03, 2026
Week 3, October 2026: The Evolving Role of Biomarkers in Antibody-Based Cancer Therapies

Antibody-based cancer therapies have expanded treatment options across multiple ……

Oct 21, 2026

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.